Olivier Bouché on Muck Rack

Olivier Bouché

Verified
Paris
As seen in: Dedicate Digital, Nature, JAMA Oncology, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Olivier

Contact Olivier, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FASHION WITH PURPOSE / LA MODE AVEC UN SENS

|
By Olivier Bouché Verified
| Dedicate Digital
De retour de la Slow Fashion Week Marseille, un événement qui pendant quelques jours transforme la ville en espace dédié à la mode et la création. Portée par le collectif BAGA et soutenue par la Ville de Marseille la Slow Fashion Week, deuxième édition, met à l’honneur une mode plus responsable et engagée.
Open in Who Shared Issue with article?

Undiz X Playboy

|
By Olivier Bouché Verified
| Dedicate Digital
Voici la collab qui vous transportera dans l’univers des playmates du bon vieux Hugh. T-shirts, shorts, ensemble assortis, le must have de l’été pour vous amuser autour d’un look effortless et sexy. undiz.com
Open in Who Shared Issue with article?

Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study

|
By Emmanuelle Samalin, Anthony Turpin, Hélène Senellart, Ludovic Evesque, Olivier Bouché Verified, Anthony Lopez, David Tougeron, Aziz Zaanan, Meher Ben Abdelghani, Olivier Dubreuil, Audrey Hennequin, Alexandre Harlé, Alix Mérigout, Faiza Khemissa, Christelle De La Fouchardière, Slimane Dermeche, Damien Botsen, Emmanuel Guardiola, Nicolas De Sousa Carvalho
| Nature Verified
Abstract Cell-free DNA (cfDNA) analysis is an emerging tool for diagnosis, prognosis, and monitoring in cancer. This ancillary study of the REGIRI-PRODIGE 58 trial (NCT03722108) evaluated cfDNA dynamics in patients with metastatic gastroesophageal adenocarcinoma (mGA) treated with regorafenib plus irinotecan. Plasma samples from 34 patients in the experimental arm were analyzed (239 samples at baseline, post-treatment initiation [days 2, 8, 15 of Cycle 1; days 1, 8, 15 of Cycle 2]).
Open in Who Shared Issue with article?
See all 153 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified